St. Luke's Roosevelt Hospital, Columbia University College of Physicians and Surgeons, New York, New York 10019, USA.
J Am Coll Cardiol. 2011 Feb 1;57(5):590-600. doi: 10.1016/j.jacc.2010.07.053.
The purpose of this study was to evaluate the antihypertensive efficacy of hydrochlorothiazide (HCTZ) by ambulatory blood pressure (BP) monitoring.
HCTZ is the most commonly prescribed antihypertensive drug worldwide. More than 97% of all HCTZ prescriptions are for 12.5 to 25 mg per day. The antihypertensive efficacy of HCTZ by ambulatory BP monitoring is less well defined.
A systematic review was made using Medline, Cochrane, and Embase for all the randomized trials that assessed 24-h BP with HCTZ in comparison with other antihypertensive drugs.
Fourteen studies of HCTZ dose 12.5 to 25 mg with 1,234 patients and 5 studies of HCTZ dose 50 mg with 229 patients fulfilled the inclusion criteria. The decrease in 24-h BP with HCTZ dose 12.5 to 25 mg was systolic 6.5 mm Hg (95% confidence interval: 5.3 to 7.7 mm Hg) and diastolic 4.5 mm Hg (95% confidence interval: 3.1 to 6.0 mm Hg) and was inferior compared with the 24-h BP reduction of angiotensin-converting enzyme inhibitors (mean BP reduction 12.9/7.7 mm Hg; p < 0.003), angiotensin-receptor blockers (mean BP reduction 13.3/7.8 mm Hg; p < 0.001), beta-blockers (mean BP reduction 11.2/8.5 mm Hg; p < 0.00001), and calcium antagonists (mean BP reduction 11.0/8.1 mm Hg; p < 0.05). There was no significant difference in both systolic (p = 0.30) and diastolic (p = 0.15) 24-h BP reduction between HCTZ 12.5 mg (5.7/3.3 mm Hg) and HCTZ 25 mg (7.6/5.4 mm Hg). However, with HCTZ 50 mg, the reduction in 24-h BP was significantly higher (12.0/5.4 mm Hg) and was comparable to that of other agents.
The antihypertensive efficacy of HCTZ in its daily dose of 12.5 to 25 mg as measured in head-to-head studies by ambulatory BP measurement is consistently inferior to that of all other drug classes. Because outcome data at this dose are lacking, HCTZ is an inappropriate first-line drug for the treatment of hypertension.
本研究旨在通过动态血压监测评估氢氯噻嗪(HCTZ)的降压疗效。
HCTZ 是全球最常用的降压药物。超过 97%的 HCTZ 处方剂量为每天 12.5 至 25 毫克。动态血压监测下 HCTZ 的降压疗效定义不明确。
使用 Medline、Cochrane 和 Embase 系统检索了所有评估 HCTZ 与其他降压药物相比 24 小时血压的随机试验。
14 项 HCTZ 剂量为 12.5 至 25 毫克的研究纳入了 1234 例患者,5 项 HCTZ 剂量为 50 毫克的研究纳入了 229 例患者,符合纳入标准。HCTZ 剂量为 12.5 至 25 毫克时,24 小时收缩压下降 6.5mmHg(95%置信区间:5.3 至 7.7mmHg),舒张压下降 4.5mmHg(95%置信区间:3.1 至 6.0mmHg),与血管紧张素转换酶抑制剂(平均血压降低 12.9/7.7mmHg;p < 0.003)、血管紧张素受体阻滞剂(平均血压降低 13.3/7.8mmHg;p < 0.001)、β受体阻滞剂(平均血压降低 11.2/8.5mmHg;p < 0.00001)和钙拮抗剂(平均血压降低 11.0/8.1mmHg;p < 0.05)的 24 小时血压降低相比有所下降。24 小时收缩压(p = 0.30)和舒张压(p = 0.15)降低无显著差异。然而,HCTZ 50 毫克组 24 小时血压降低显著更高(12.0/5.4mmHg),与其他药物相当。
在头对头研究中,通过动态血压监测测量,HCTZ 的日常剂量为 12.5 至 25 毫克时,其降压疗效始终不如所有其他药物类别。由于缺乏该剂量的疗效数据,HCTZ 不是治疗高血压的合适一线药物。